Amblyopia is a widespread and severe form of visual disability that originates in childhood and persists into adulthood. Currently, the primary treatment for amblyopia involves patching or blurring the vision in the stronger eye. However, this treatment is ineffective beyond 10 years of age, is hampered by poor compliance, and does not promote recovery of binocular vision. The technology described has proven effective in both juvenile and adult animals, and provides a treatment strategy that circumvents compliance issues. Meanwhile, it maintains the primary advantage of the current treatment in that it is a minimally invasive strategy for treating a brain disorder.